Physostigmine holds patents for treating dementia and Alzheimer’s disease as well as inhibiting butyrylcholinesterase, acetylcholinesterase inhibition, and memory enhancement. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.